<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119457</url>
  </required_header>
  <id_info>
    <org_study_id>TTP889-201</org_study_id>
    <secondary_id>Eudract CT#2004-002511-83</secondary_id>
    <nct_id>NCT00119457</nct_id>
  </id_info>
  <brief_title>Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)</brief_title>
  <official_title>A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TTP889 prevents venous thromboembolism
      following surgery to repair hip fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FIXIT is the first Phase 2 study of TTP889. The trial is a proof-of-concept study to
      determine the safety and antithrombotic efficacy of TTP889 in patients at risk for venous
      thromboembolism (VTE). The study is a multi-center, randomized, double-blind, parallel-group
      evaluation of 300 mg TTP889 or placebo, administered orally once daily for three weeks, in
      patients who have undergone surgery to repair unilateral fracture of the upper third of
      either femur and who have completed 5 to 9 days of postoperative prophylactic treatment for
      VTE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety of once daily oral administration of TTP889 for three weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the correlation between peak and trough plasma concentrations of TTP889 and clinical safety and efficacy outcomes.</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Embolism and Thrombosis</condition>
  <condition>Hip Fractures</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP889</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have undergone reparative surgery within 72 hours after unilateral hip fracture,
             defined as fracture of the upper third of either femur

          -  Must have started standard prophylactic treatment for VTE with low molecular weight
             heparin (LMWH) or heparin before surgery or within 24 hours after hip fracture
             surgery, and continued treatment with LMWH or heparin for at least five days, but not
             more than nine days, after surgery

          -  Last dose of LMWH or heparin must have been administered at least 12 hours, but not
             more than 48 hours, before dosing with study drug

          -  Females must have a negative serum pregnancy test

          -  Must weigh at least 45 kg

          -  Must demonstrate the mental and physical ability and willingness to follow all
             study-specific instructions

          -  Must be able to read, comprehend and sign the Ethics Committee-approved informed
             consent form

        Exclusion Criteria:

          -  Evidence of active bleeding

          -  Clinical signs of VTE

          -  Any medical requirement for (or intention to use) continued anticoagulation after
             randomization through the end of study

          -  History of intracranial bleeding, hemorrhagic stroke, or gastrointestinal bleeding
             within 3 months of study start

          -  Presence of active malignant disease

          -  Hip fracture associated with multiple trauma, that places patient at excessive risk
             for hemorrhage or organ system failure, or that may make it difficult or impossible to
             perform bilateral lower limb venography

          -  Intention to take aspirin at doses greater than 325 mg/day

          -  Hemoglobin &lt; 5.45 mmol/L (9 g/dL), hematocrit &lt; 29%, or a platelet count &lt; 100,000/mL
             at the screening visit

          -  Elevated ALT or AST level &gt; 3.0 times the ULN, or an elevated total bilirubin &gt; 1.5
             the ULN at the screening visit

          -  Creatinine &gt; 180 mmol/L (2.0 mg/dL) at the screening visit

          -  Any other laboratory value at screening that the Investigator considers to be
             clinically significant and warrants exclusion from the study

          -  Patient is currently breast feeding a child and wishes to continue breast feeding

          -  Previous allergy to contrast material or any other contraindications to perform
             bilateral lower limb venography

          -  The use of another investigational drug within 28 days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt I Eriksson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Orthopaedics, Goteborg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David P Ward, MD</last_name>
    <role>Study Director</role>
    <affiliation>vTv Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice, Urazove oddeleni</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN s Poliklinikou Ostrava, Traumatologicke Centrum</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Motol, Ortopedicka Klinicka UK 2.LF a FN Notol</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Na Bulovce, Ortopedicka Klinika IPVZ a 1.LF UK ORT, Budinova 2</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VFN, I. Chirurgicka klinika</name>
      <address>
        <city>Praha-2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAlborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopaedkirurgisk Klinik, Farso</name>
      <address>
        <city>Farso</city>
        <zip>9640</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amtsygehuset i Gentofte</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAS Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horsholm Hospital</name>
      <address>
        <city>Horsholm</city>
        <zip>2970</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Bispebjerg Hospital</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silkeborg Hospital</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedics, Alesund Sykehus</name>
      <address>
        <city>Alesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyehuset Innlandet HF</name>
      <address>
        <city>Gjovik</city>
        <zip>2819</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyehuset Innlandet HF</name>
      <address>
        <city>Lillehammer</city>
        <zip>2609</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halfdan Wilhelmsens Alle 17</name>
      <address>
        <city>Tonsberg</city>
        <zip>3116</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortoped Kliniken, Sahlgrenska Universitetssjukhus, Ostra</name>
      <address>
        <city>Goteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopedsektionen, Kirurgkliniken, Kungalvs Sjukhus</name>
      <address>
        <city>Kungalv</city>
        <zip>442 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortoped kliniken, Sahlgrenska Universitetssjukhus</name>
      <address>
        <city>Molndal</city>
        <zip>431 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortoped kliniken, NU-sjukvarden, Udevalla Sjukhus</name>
      <address>
        <city>Udevalla</city>
        <zip>451 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortoped kliniken, Sjukhuset i Varberg</name>
      <address>
        <city>Varberg</city>
        <zip>432 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2005</study_first_submitted>
  <study_first_submitted_qc>July 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <keyword>antithrombotic agents</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>embolism</keyword>
  <keyword>deep vein thrombosis</keyword>
  <keyword>hip fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

